RESTRICTIVE PRACTICES IN RESIDENTIAL AGED CARE IN AUSTRALIA

BACKGROUND PAPER 4

MAY 2019
The Royal Commission into Aged Care Quality and Safety was established on
8 October 2018 by the Governor-General of the Commonwealth of Australia,
His Excellency General the Honourable Sir Peter Cosgrove AK MC (Ret’d).
Replacement Letters Patent were issued on 6 December 2018.

The Honourable Richard Tracey AM RFD QC and Ms Lynelle Briggs AO have been
appointed as Royal Commissioners. They are required to provide an interim report
by 31 October 2019, and a final report by 30 April 2020.

The Royal Commission intends to release consultation, research and background
papers. This background paper has been prepared by staff of the Office of the
Royal Commission, for the information of Commissioners and the public. The views
expressed in this paper are not necessarily the views of the Commissioners.

This paper was published on 3 May 2019.

© Commonwealth of Australia 2019

ISBN 978-1-920838-73-7 (online)

With the exception of the Coat of Arms and where otherwise
stated, all material presented in this publication is provided
under a Creative Commons Attribution 4.0 International licence.
For the avoidance of doubt, this means this licence only applies
to material as set out in this document.

The details of the relevant licence conditions are available on
the Creative Commons website as is the full legal code for the
CC BY 4.0 licence <www.creativecommons.org/licenses>.

The terms under which the Coat of Arms can be used are detailed
on the Department of the Prime Minister and Cabinet website
Introduction

This paper provides a high-level introduction to restrictive practices in residential aged care in Australia. It has been prepared by staff of the Office of the Royal Commission into Aged Care Quality and Safety but does not represent a direction or position of the Royal Commission in relation to this area. Any views expressed are not necessarily the views of the Commissioners.

The use of restrictive practices in residential aged care in Australia is contentious. There is significant public interest in the issue of restraint and ways to reduce or avoid it. Numerous media reports and inquiries have highlighted accounts of the misuse or overuse of physical restraint and psychotropic medication.¹ This includes personal accounts from members of the public about residents being physically restrained frequently, or for long periods of time, or restrained without consent.²

Restrictive practices can elicit concern for a number of reasons. Fundamentally, they impact on the liberty and dignity of the care recipient.³ In circumstances where they are not absolutely necessary, their use is likely to sit uncomfortably for many.⁴ Their use without lawful consent may infringe the resident’s legal rights and constitute a civil or criminal offence, such as assault or false imprisonment, although there are very few cases in Australia where a criminal or civil complaint has been pursued to challenge the use of a restraint in an aged care setting.⁵

Physical and chemical restraint can have significant adverse effects on a resident, both physically and psychologically. There are also fundamental questions about their effectiveness.

⁴ See, for example, J Ibrahim, Physical restraint doesn’t protect patients—there are better alternative, The Conversation, 11 February 2019, viewed 26 April 2019, https://theconversation.com/physical-restraint-doesnt-protect-patients-there-are-better-alternatives-111060.
Some inquiries have recommended greater regulation of restrictive practices in aged care in Australia.6 In April 2019, the Minister for Senior Australians and Aged Care, the Hon Ken Wyatt AM, MP, introduced new requirements concerning the use of restraint in residential aged care services in Australia. These requirements apply to government-funded aged care providers under the Aged Care Act 1997 (Cth) from 1 July 2019.

What are restrictive practices?

The term restrictive practices refers to activities or interventions, either physical or pharmacological, that have the effect of restricting a person’s free movement or ability to make decisions. Restrictive practices are commonly referred to in the context of residential aged care as practices that control the behaviour of a resident, which may occur with the intention of reducing risks to a resident or others.

Physical restrictive practices

Common restrictive practices in residential aged care that are physical in nature include:

- clasping a person’s hands or feet to stop them from moving;
- applying lap belts, leg, wrist, ankle, or vest restraints;
- attaching bed rails, locking over bed or chair tray tables;
- seating residents in chairs with deep seats, or rockers and recliners, that the resident cannot stand up from, or removing their mobility aids.

Restrictive practices may also include confining a person in a residential facility or specialised unit.7

Pharmacological restrictive practices

Particular medicines prescribed for residents in residential aged care can have the effect of restricting their movements or ability to make decisions. Medications that cause sedation such as mirtazapine, benzodiazepines and opioids prescribed for pain relief have potential to have a restrictive effect. Opioids such as oxycodone, oxycodone plus naloxone, buprenorphine patch, and fentanyl patch have the highest utilisation rate in people aged over 75 years (per 1000 population aged 75 years and older).8

The most common type of medications that can have the effect of restricting a person’s movements or ability to make decisions are psychotropic medications, capable of affecting

---

Australian Law Reform Commission, above n 3, p 11.

7 Australian Law Reform Commission, above n 3, p 143.

the mind, emotions and behaviours of a person. They include stimulants, antidepressants, antipsychotics, mood stabilizers and anti-anxiety agents. In aged care, they are most commonly prescribed in response to exhibited behavioural or psychological symptoms of dementia (commonly referred to as BPSD or neuropsychiatric symptoms).

Modern psychotropic medications have been around since about the 1950s when the first antipsychotics, monoamine-oxidase inhibitor antidepressants, and anxiolytic/hypnotic sedatives, called benzodiazepines were developed. These medicines revolutionised the treatment of mental illness and were often safer than older medicines such as barbiturates, prominent in the first half of the 1900s. However, they were still associated with potentially severe side effects and could be fatal in the case of overdose. The development of these medicines gave way to a better understanding of the underlying biochemical disturbances associated with mental illness. This was used to develop newer, more targeted drugs with less risk for extrapyramidal side effects (i.e. involuntary and uncontrollable movements including twitches, jerking, twisting, restlessness), including the antipsychotics that currently dominate the Australian market, such as quetiapine, olanzapine and risperidone. A list of the most common psychotropic and other drugs relevant to chemical restraint and aged care, together with their clinical indications, is at the Appendix.

Prescription and administration of psychotropic medications may occur for the purposes of treating a resident with a diagnosed illness or condition. Use of such medications may not be recognised as restrictive practices, or restraint, unless the apparent purpose of using the medication is to restrict the resident’s movement or ability to make decisions, as opposed to treatment of a particular illness.

Variations in defining physical and chemical restraint

Definitions of physical and chemical ‘restraint’ and ‘restrictive practices’ used in legislation, guidance, research papers and reports vary in terms of: the terminology used; the precise categorisation of restraints; the breadth of activities recognised as restraint; and the relevance of the purpose of the activity in determining whether a practice constitutes a restraint. For example:

- The recent Quality of Care Amendment (Minimising the Use of Restraints) Principles 2019 effective from 1 July 2019 broadly define physical restraint as any practice, device or action (other than chemical restraint or medication used for treatment of a mental disorder, physical illness or condition) that interferes with a ‘consumer’s’ ability to make a decision or restricts a consumer’s free movement.

Chemical restraint is, however, characterised by the purposes for which a medication is used. Medication that has been prescribed for the purposes of

---

T Ban, ‘Fifty years chlorpromazine: a historical perspective’ (2007) 3 Neuropsychiatric Disease and Treatment 495.
12 Quality of Care Amendment (Minimising the Use of Restraints) Principles 2019, section 4.
treatment of a mental disorder, physical illness or condition is not characterised as restraint for the purposes of the Principles.

- The Department of Health’s Decision-Making Tool: Supporting a Restraint Free Environment in Residential Aged Care 2012 states that restraint is ‘any aversive practice, device or action that interferes with any person’s ability to make a decision or which restricts their free movement’.\(^{13}\)

Physical restraint is described within the guidance as ‘the intentional restriction of a resident’s voluntary movement or behaviour by the use of a device, or removal of mobility aids, or physical force for behavioural purposes’.\(^{14}\)

The guidance as to what constitutes chemical restraint requires consideration of whether the medication is necessary for the treatment of an identified medical condition.\(^{15}\) This might require consideration of the specific medication used, dose and dosing schedule.\(^{16,17,18}\)

- The Department of Social Services’ National Framework for Reducing and Eliminating the Use of Restrictive Practices in the Disability Service Sector defines restrictive practices as ‘any intervention that has the effect of restricting the rights or freedom of movement of a person with disability with the primary purpose of protecting the person or others from harm’.\(^{19}\)

Physical restraint is defined as the sustained or prolonged use or action of physical force to prevent, restrict or subdue movement of a person’s body, or part of their body, for the primary purpose of influencing a person’s behaviour.\(^{20}\)

Chemical restraint is defined as the use of medication or chemical substance for the primary purpose of influencing a person’s behaviour or movement, but does not include the use of medication prescribed by a medical practitioner for the treatment, or to enable treatment, of a diagnosed mental disorder, a physical illness or physical condition.\(^{21}\)

- The Australian Commission on Safety and Quality in Health Care’s National Safety and Quality Health Service Standards, 2017 defines restraint more narrowly as the ‘restriction of an individual’s freedom of movement by physical or mechanical means’.\(^{22}\) It contends that there is a lack of consensus on the definition of chemical/pharmacological restraint because of difficulties in determining whether a clinician’s intent is primarily to treat a person’s symptoms or to control their behaviour.\(^{23}\)

\(^{13}\) Department of Health and Ageing, above n 7, p 1.

\(^{14}\) Ibid, p 24.


\(^{16}\) The Royal Australian & New Zealand College of Psychiatrists, Professional Practice Guideline 10—Antipsychotic medications as a treatment of behavioural and psychological symptoms of dementia, August 2016.

\(^{17}\) Therapeutic Guidelines Ltd (eTG April 2019 edition).


\(^{19}\) Department of Social Services, National Framework for Reducing and Eliminating the Use of Restrictive Practices in the Disability Service Sector, 2013, p 4.

\(^{20}\) Ibid, p 5.

\(^{21}\) Ibid, p 5.

\(^{22}\) Australian Commission on Safety and Quality in Health Care, National Safety and Quality Health Service Standards, 2017, p 75.

\(^{23}\) Australian Commission on Safety and Quality in Health Care, National Safety and Quality Health Service Standards: Guide for Hospitals, 2017, p 322.
• The Department of Health’s *National Standards for Mental Health Services, 2010* defines restraint as a ‘restrictive intervention that relies on external controls to limit the movement or response of a person’.24

Variations in definitions of restraint reflect challenges in conceptualising and identifying restraint in practice. For instance, inappropriate prescription or administration of medication might not be recognised as restraint if it has been prescribed to treat a diagnosed illness or condition. Recognising restraint as a practice intended to avoid harm may conflate the justification for restraint with the impact on the resident and obscure the significance of perceptions of risk, including the risks associated with restraint itself. Secluding or confining a person to a residence or a locked dementia unit may not be recognised as restraint, although such practices can significantly inhibit a resident’s liberty to move within or outside the residence.

**The effects of restrictive practices**

**Physical restraint**

While in certain circumstances, physical restraint may be necessary to mitigate risks to a resident or others in an emergency, empirical evidence demonstrates that restrictive practices can cause death, as well as other serious physical and psychological consequences that may increase morbidity, or expedite the dying process.25 Adverse impacts of physical restraint on a person can include:

- fear, shame, anxiety, loss of dignity26, agitation27, depression28, lower cognitive performance;29

---

28 Ibid.
N Castle, above n 27.
• bruising, direct skin injuries, pressure injuries, contractures, respiratory complications, urinary and faecal incontinence and constipation, under nutrition, reduced mobility and increased dependence in activities of daily living, impaired muscle strength and balance, reduced cardiovascular endurance; serious injury and mortality.

There are also questions about the effectiveness of physical restraint in reducing or avoiding harm. For example, a recent study into the nature and extent of physical restraint-related deaths in nursing homes affirmed the view that individuals still experience falls even when restrained to prevent them. The literature also suggests that physical restraints are not effective in preventing serious injury as a consequence of aggressive behaviour. In many cases, the agitation, discomfort and anxiety of the resident is only increased.

Some academics argue that there is sufficient empirical evidence to support the idea that, in many cases, physical restraint causes more harm than benefit.

**Chemical restraint**

Pharmacological approaches for the treatment of the behavioural and psychological symptoms of dementia may be effective for some people with severe agitation and aggression associated with risk of harm, delusions and hallucinations or comorbid pre-existing mental health conditions. However, the use of psychotropic medicines is also associated with increased risk of serious adverse events, and their overuse or misuse may have significant impacts on a person’s health, including:

• sedation, gait disturbances and increased risk of falls and fractures;
• urinary tract infections or incontinence;

---

31 C Gastmans, K Milisen, above n 27.
33 Ibid.
34 C Gastmans, K Milisen, above n 27.
35 C Peisah, E Skladzien, above n 25, p 11.
36 C Gastmans, K Milisen, above n 27.
37 N Castle, J Engberg, above n 31.
38 C Gastmans, K Milisen, above n 27.
39 J Enberg, N Castle, D McCaffrey, above n 29.
40 C Gastmans, K Milisen, above n 27.
41 N Castle, J Engberg, above n 31.
43 C Gastmans, K Milisen, above n 27.
44 Ibid.
45 D Evans, J Wood and L Lambert, above n 30.
48 N Bellenger, J Ibrahim et al., above n 25.
49 C Gastmans, K Milisen, above n 27.
50 Ibid.
51 The Royal Australian & New Zealand College of Psychiatrists, above n 16.
• increased cognitive impairment and confusion;
• constipation and associated risk for faecal impaction and bowel obstruction;
• increased risk for extrapyramidal side effects (drug-induced movement disorders including restlessness and agitation);
• increased risk of respiratory complications (such as pneumonia), stroke and heart rhythm abnormalities, cerebrovascular events (including stroke) and increased risk of death.44

In at least one recent coronial inquiry in Victoria, an inappropriate oxazepam (a benzodiazepine) regime prescribed to a person living with dementia in a residential aged care facility was linked to a number of falls, causing multiple fractures, and was found to have contributed to her physical decline and death.45 The Coroner referred his findings to the (then) Australian Aged Care Quality Agency and to the Royal Australian College of General Practitioners relating to, among other things, the inappropriate prescription and administration of the medication oxazepam on an ‘as required’ basis. There is a body of literature establishing that long-term use of benzodiazepines is associated with significant long-term cognitive impairment and increased risk of dementia.46

In the United States, the Food and Drug Administration issued a safety alert in 2005 concerning the increased risk of death for dementia patients prescribed antipsychotic drugs.47

44 Ibid.
C Peisah, E Skladzien, above n 25, pp 12, 19.
47 United States Food and Drug Administration, FDA Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioural disturbances, 11 April 2005.
Can restrictive practices be reduced or avoided?

Whether either physical or pharmacological restrictive practices are necessary in residential aged care is contentious. Some submissions to the Australian Law Reform Commission’s enquiry on Elder Abuse, for example, expressed the view that restraint in residential care should be a last resort, but is sometimes necessary to protect the resident or staff. Others questioned whether restrictive practices are ever necessary, advocating that the focus should instead be on alternatives that reflect personalised care. Many raised concerns about their overuse.48

In practice, physical and pharmacological restrictive practices are often used on people with cognitive impairment who exhibit challenging behaviour, including people exhibiting the behavioural and psychological symptoms of dementia. Behaviours associated with these symptoms that may cause concern include agitation or extreme restlessness, physical and verbal aggression, wandering, and social and/or sexual disinhibition. The psychological symptoms present in someone with dementia may include delusions, hallucinations, apathy, depression and anxiety.49 These symptoms are unique to the person and their circumstances and may be made worse by contributing factors such as pain, fear, feelings of being threatened or stress associated with confusing environments and side effects of medications that contribute to anticholinergic burden, sedation, delirium and movement disorders.50 Background Paper 3—Dementia in Australia: nature, prevalence and care includes further discussion about the behavioural and psychological symptoms of dementia.

There is an emerging body of evidence and guidance on strategies and non-pharmacological interventions to negate or mitigate the need for restraint by managing the underlying causes of challenging behaviour. Some of the key considerations emerging from the literature include:

- Environmental, e.g. measures to reduce risk of falls or confusion such as non-slip flooring and footwear, improved lighting, signage, appropriate beds and seating, mobility aids, reduced environmental noise, alarm systems.51 One international study indicated that in terms of the layout of the residential aged care facility, the significant factors include keeping a small number of residents in each living area, adopting a straight layout of the circulation system without any changes in direction and only one dining room.52

---

48 Australian Law Reform Commission, above n 3, p 144.
51 ‘Anticholinergic burden’ refers to the cumulative effect of using multiple medications that block the effects of the neurotransmitter acetylcholine in the body and is associated with significant adverse side effects including blurred vision, constipation, delirium, confusion and cognitive impairment.
• Psychosocial, e.g. engaging familiar staff, provision of sensory aids and appropriate sensory stimulation, therapies and activities such as occupational therapy and activities using overlearned skills (such as gardening or folding laundry), therapeutic touch, and companionship.\textsuperscript{53}

• Care approach, e.g. individualised routines, increased supervision and staff interaction, appropriate staffing level and mix, regular evaluation and monitoring of conditions affecting behaviour.\textsuperscript{54}

• Physiological, e.g. comprehensive medical examination and review of medication (including medication that may contribute to worsening cognitive function, restlessness and agitation\textsuperscript{55}), nutrition and hydration management, treating infections, pain management.\textsuperscript{56}

There are requirements to attempt non-pharmacological interventions before prescribing any psychotropic medications to manage challenging behaviours. For example, when prescribing risperidone, a medication approved in Australia and New Zealand for the use of behavioural disturbances associated with Alzheimer’s type dementia, the Pharmaceutical Benefits Scheme (PBS) requires that non-pharmacological methods of treatment be tried first. Only after the patient has failed to respond, can the medication be validly prescribed under that scheme.\textsuperscript{57}

The Royal Australian and New Zealand College of Psychiatrists’ \textit{Professional Practice Guideline 10: Antipsychotic medications as a treatment of behavioural and psychological symptoms of dementia} states that the first line approach to management of the behavioural and psychological symptoms of dementia is a person-centred, psychosocial multidisciplinary treatment plan. Use of antipsychotic medications are recommended when symptoms are psychotic in nature, unresponsive to psychosocial interventions or there is a severe and complex risk of harm. They are not recommended for symptoms such as wandering, undressing, inappropriate voiding, verbal aggression or screaming.\textsuperscript{58}

Even when psychotropic medication is prescribed, the available literature suggests that non-pharmacological strategies, such as social interaction interventions, be co-administered to mitigate any potential negative effects of the latter on behavioural and psychological symptoms.\textsuperscript{59}


\textsuperscript{54} Ibid.


\textsuperscript{56} K Burns, R Jayasinha, R Tsang, H Brodaty, above n 53.

\textsuperscript{57} See also C Peisah, E Skladzien, above n 25, p 14.

\textsuperscript{58} Department of Health and Ageing, above n 7, p 3.

\textsuperscript{59} Australian Commission on Safety and Quality in Health Care, \textit{Preventing Falls and Harm from Falls in Older People: Best practice Guidelines for Australian Residential Aged Care Facilities}, 2009.


\textsuperscript{59} Royal Australian and New Zealand College of Psychiatrists, above n 16.


\textsuperscript{59} C Ballard, M Orrell, S YongZhong, E Moniz-Cook, J Stafford, R Whittaker, et al., ‘Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-
Despite the emerging evidence about non-pharmacological interventions to negate or mitigate the need for restraint, research indicates that barriers to their use in aged care facilities include:60

- perceptions about safety, fear of resident injury and legal concerns;61
- residential facility characteristics such as staff and resource constraints and organisational culture;62
- lack of knowledge about effects of restraints and alternative practices;63
- beliefs and expectations of staff, family and residents, including a paternalistic attitude towards older people;64
- inadequate review;65
- communication barriers.66

A submission from the Australian and New Zealand Society for Geriatric Medicine to the Australian Law Reform Commission’s enquiry on Elder Abuse indicated that inappropriate use of drugs was a practice ‘driven by lack of skills and knowledge as well as staffing numbers.’67 In another earlier enquiry it was observed further barriers to reducing or avoiding restraint in residential aged care may include funding models, complexity of the care needs of residents and inadequate collaboration between health professionals and residential aged care staff.68

A range of studies have considered the effectiveness of organisational interventions aimed at reducing physical and chemical restraint, including education programs, consultancy support, randomised controlled trial by the well-being and health for people with dementia (WHELD) program’ (2016) 173(1) American Journal of Psychiatry 252.


See also K Carnell and R Paterson, above n 6, p 120.

62 K Moore, B Haralambous, above n 61.

63 K Moore, B Haralambous, above n 61.

64 K Moore, B Haralambous, above n 61.

65 K Moore, B Haralambous, above n 61.

66 Ibid.

67 Australian Law Reform Commission, above n 3, p 143.

68 K Carnell and R Paterson, above n 6, p 120.
implementation of organisational policies and medication reviews, with varying results.69 Development of strategies to reduce or avoid restrictive practices might consider the institutional aspects of residential care that generate an environment and culture in which residents’ ability to exercise autonomy is limited, as well as promoting evidence-based practice for management of the behavioural and psychological symptoms of dementia.70

How prevalent is the use of restrictive practices in Australia?

There are currently no comprehensive national data on the use of restrictive practices in residential aged care facilities in Australia. Residential aged care service providers have not been required to record and report on the use of restraint or restrictive practices on residents, although the Australian Government’s National Aged Care Quality Indicator Program will introduce reporting requirements relating to physical restraint from 1 July 2019. Varying definitions of restraint, discussed above, also impact upon the data about prevalence.

Some international studies indicate that the use of physical restraint practices can vary significantly between countries and between residential aged care facilities.71 There is a lack of available data demonstrating the prevalence of physical restraint in residential care in contemporary Australia.72 Some older research provides at least some indication. A series of studies published between 1997 and 1998 concerning physical restraint in residential care facilities in Western Australia, Queensland, Victoria and New South Wales, found that 15–26% of residents in participating care homes were being physically restrained at the time of

---


survey. A study carried out in a high care facility in Western Australia in 2005 found that 40% of residents were restrained.

A 2009 study in 44 residential aged care homes in Sydney found that about half of the residents were being prescribed psychotropic medications. A more recent national Australian study of residents in residential aged care facilities found that nearly two-thirds were regularly taking psychotropic medication. A recent international study found that about one-third of people with dementia were prescribed antipsychotic medications. A recent literature review of studies of Australian aged care facilities found that the proportion of residents prescribed antipsychotic medication ranged from 13 to 42%. The Third Australian Atlas of Health Care Variation 2018 reported Pharmaceutical Benefits Scheme data indicating that the number of people over the age of 65 years being dispensed antipsychotic medications had fallen since 2013–14. However, there was no major change in the overall volume of antipsychotic medications dispensed and variation in dispensing had increased.

While studies have provided evidence that antipsychotic medication for people with dementia should be reviewed regularly, and that medication may be successfully reduced or discontinued, there is evidence of long-term use of antipsychotics among patients living with dementia in residential aged care facilities.

Several inquiries have heard concerns about the prevalence and inappropriate use of psychotropic medication in aged care. The Australian and New Zealand Society for Geriatric Medicine submitted to the Australian Law Reform Commission’s enquiry on Equality, Capacity and Disability in Commonwealth Laws that restrictive practices are ‘still pervasive’ in residential aged care facilities, ‘particularly in relation to chemical sedation and

---


inappropriate use of drugs’. 81 The National Prescribing Service has also highlighted evidence of over use of psychotropic medication. 82

**How are restrictive practices in aged care regulated in Australia?**

There is a ‘patchwork’ of federal, state and territory laws, plus non-statutory policies and guidance that are relevant to restrictive practices in a residential aged care context. 83 These include the aged care regulatory framework and guidance, health and medication regulation and guidance, and legal frameworks relating to consent to care and treatment. Restrictive practices should also be considered in the context of Australia’s human rights obligations.

**Aged care regulatory framework and guidance**

**The Aged Care Act**

The *Aged Care Act 1997* (Cth) (the Act) is the principal legislation regulating aged care in Australia. Aged care providers that receive government funding are required to comply with responsibilities under the Act concerning accountability, user rights and quality of care principles. Residential aged care services must meet standards set out in Quality of Care Principles issued under the Act to be eligible for government funding.

Under the Act, responsibilities of approved providers include:

- provision of care consistent with residents’ rights to live in a safe, secure and homelike environment, and to move freely both within and outside the residential care service without undue restriction; 84
- systems to identify and ensure compliance with all relevant legislation, regulatory requirements, professional standards, and guidelines; 85
- effective management of challenging behaviours; 86
- safe and correct management of medication. 87

There are inferences that may be drawn from these responsibilities of residential aged care providers under the Act. For example, residents might reasonably expect that they will not be subject to unnecessary restrictive practices. It might be inferred that providers will ensure that they have systems in place to identify and comply with laws concerning consent to care and treatment, medication administration and professional guidelines concerning the use of restraints.

---

81 Australian Law Reform Commission, above n 3, p 143.
83 Australian Law Reform Commission, above n 3, p 144.
84 *Aged Care Act 1997*, Schedule 1 User Rights Principles 2014, Charter of Care Recipients’ Rights and Responsibilities—Residential Care part 1(g).
85 Quality of Care Principles 2014, schedule 2, part 1, item 1.2.
86 Ibid, item 2.13.
87 Ibid, item 2.7.
Guidance issued to assist accreditation assessors determine compliance with the standards includes guidance relating to these requirements. The guidelines indicate that effective management of challenging behaviour should comprise individualised assessment and care planning processes that include the resident and others who are able to inform strategies to meet the needs of the resident, with restraint only used as a last resort. The provider should be able to demonstrate that it has processes in place for administration of medication that are safe and consistent with legislation and professional guidelines, and that residents are satisfied with management of their medications. The provider should ensure regular evaluation and review of the resident’s medication needs and preferences with a pharmacist or medical officer.

The Australian Government’s (non-statutory) guidance applicable to providers includes guidance concerning the use of restrictive practices and medication management in residential aged care facilities. The Australian Commission on Safety and Quality in Health Care has also produced guidance on preventing falls in residential aged care, which includes guidance on use of restraint.

Recent changes to regulation under the Act

The Australian Government has announced a number of changes to the regulation of aged care service providers under the Act that will come into effect from 1 July 2019.

A new single set of quality standards applicable across aged care service types, will replace existing standards. The new standards require providers to demonstrate, for example, each consumer is supported to exercise choice and independence; a service environment that enables consumers to move freely indoors and outdoors; ongoing assessment and planning with consumers; and, where clinical care is provided, a clinical governance framework that includes minimising use of restraint.

To support compliance with the new standards, the Aged Care Quality and Safety Commission has published Guidance and Resources for Providers to Support the Aged Care Quality Standards, 2019, which includes guidance on demonstrating compliance with standards concerning minimisation of restraint. The provider is required to demonstrate that restrictive practices are only used when absolutely necessary, as a last resort and in accordance with professional guidance and best practice. Organisational systems should limit and monitor use of restraint.

The Quality of Care Amendment (Minimising the Use of Restraints) Principles 2019 will impose obligations on providers that include ensuring that an assessment is carried out by a...
Health practitioner who has concluded that restraint is required and that the reasons for the restraint and any alternatives to restraint that have been used are documented in the resident’s care and services plan. The provider must regularly monitor the resident for signs of distress or harm while the resident is subject to the restraint.

From 1 July 2019, it will be mandatory for residential aged care service providers to provide data on three quality indicators, including use of physical restraint, to the Department of Health. Resources have been developed to assist residential services to collect and report quality indicator data.99 The Government has announced that it intends to publish the data by the end of 2019, although the Government has not announced the form the data will be presented in.

**Health practitioner regulation**

Health professionals, including pharmacists, medical practitioners, nurse practitioners including registered and enrolled nurses, who may be employed by or providing services to residents in residential aged care, are subject to regulation under national, state and territory legislation, including with respect to medication management.

Each of the states and territories has implemented legislation that is consistent with the *Health Practitioner Regulations National Law Act 2009* (Qld) (national law) providing for regulation and accreditation of health practitioners, although there are differences in how the national law operates in each of the states and territories.

National boards are the principal regulatory bodies under the national law. There are 16 health professions within the national regulation and accreditation scheme, each regulated by a national board. The Australian Health Practitioner Regulation Agency (AHPRA) provides support to national boards and administers the national regulation and accreditation scheme under the national law. A Ministerial Council comprised of ministers from each state and territory government, and the Australian Government provides policy direction and oversight of the national scheme.100

Health practitioners must meet registration standards developed by national boards and approved by the Ministerial Council for registration.101 Programs of study that qualify practitioners for registration must be accredited by an accreditation authority and approved by the relevant national board.102 The programs of study cover prescribing of medicines.

Other than in New South Wales and Queensland where alternate processes apply,103 concerns about a registered health practitioner’s performance or conduct can be raised with the Australian Health Practitioner Regulation Agency and will be considered by the relevant national board. The national law provides for voluntary notifications of concerns about practitioners, which can be made by any person,104 and imposes mandatory obligations on

---


101 *Health Practitioner Regulation National Law Act 2009* (Qld) s 38.


103 In these co-regulatory jurisdictions, notifications are managed through the relevant health complaints entities. See, for example, COAG Health Council, *Guide to the National Registration and Accreditation Scheme for health professions*, 2018.

104 *Health Practitioner Regulation National Law Act 2009* (Qld) s 145.
health practitioners, employers and education providers to report notifiable conduct.105 The national law empowers national boards to take a range of regulatory actions. For instance, national boards may suspend or impose conditions on a practitioner’s registration, caution the practitioner or accept an undertaking from the practitioner.106 A national board may establish a panel to consider concerns regarding a health practitioner107 and in some circumstances will be required to refer the matter to a relevant state or territory tribunal.108

National boards develop codes and guidelines.109 Accredited professional education providers and a range of other professional and industry associations also publish information and guidance for their members, as do government agencies. Professional guidance may not be strictly binding on health practitioners but may be referred to in administrative or legal proceedings concerning professional conduct.

In the aged care sector, personal care workers are not required to hold registration and are not subject to the national scheme. This represents approximately 70% of the total workforce providing direct care in residential aged care.110 To address concerns about unregistered health care workers, including workers within aged care, state and territory governments agreed to implement a national code of conduct for unregistered workers.111 The code of conduct regime, to the extent enacted in each state and territory, empowers state and territory health complaints entities to take action in respect of breaches of a code of conduct.112 Although, there may be some ambiguity about the extent to which personal care workers provide health services that come within the ambit of the regime, health services may have a different meaning in each state or territory legislation.113

**Medicines regulation**

Medicines regulation in Australia is performed by the Therapeutic Goods Administration. Medicines approved for sale in Australia are registered or listed on the Australian Register of Therapeutic Goods and scheduled in the Poisons Standard under the *Therapeutic Goods Act 1989* (Cth).114 Most psychotropic medicines will be classed as either schedule 4—prescription only medicines (e.g. antipsychotics, antidepressants, most benzodiazepines) or schedule 8—controlled drugs (e.g. alprazolam, a benzodiazepine, or opioid analgesics).

Registration with a national board recognises the qualification and scope of practice of health practitioners, which may include prescription, supply or administration of medicines. For instance, registered nurses in Australia are qualified to administer medicines to patients.115

---

105 Ibid, ss 141–143.
106 Ibid, ss 155, 178.
107 Ibid, s 182.
108 Ibid, ss 193–193B.
109 Health Practitioner Regulation National Law Act 2009 (Qld) s 39.
The Nursing and Midwifery Board may endorse a registered nurse as a nurse practitioner able to prescribe medication, including antipsychotics. The Nursing and Midwifery Board may endorse enrolled nurses to administer medicines if they have completed education on medication administration. However, legal authority for prescription, supply and administration of medicines is governed by legislation in each state and territory, such as the *Drugs, Poisons and Controlled Substances Act 1981* (Vic), which determines who can prescribe, supply or administer, which medicines, in which circumstances, in what manner and for what purposes. This includes requirements relating to particular classes of medicines, such as certain schedule 4 and schedule 8 medicines. The states and territories are responsible for administration of legislation relating to the supply and administration of medicines, including regulatory controls.

The Australian Health Practitioner Regulation Agency regulatory framework does not apply to personal care workers and does not authorise personal care workers to administer medication. The Australian Nursing and Midwifery Foundation has said that as the administration of medicines is within the ordinary scope of practice of registered and enrolled nurses; personal care workers should only provide assistance to people who are able to self-administer medication. However, under legislation in some jurisdictions, personal care workers with appropriate medication administration training may be allowed to administer medicines under the management or supervision of a registered nurse.

---


117 If an EN has not completed medication administration education a notation of ‘Does not hold Board-approved qualification in administration of medicines’ will be placed on their on their registration: Nursing and Midwifery Board of Australia, *Fact sheet: Enrolled nurses and medicine administration*, 2016, viewed 5 April 2019, https://www.nursingmidwiferyboard.gov.au/documents/default.aspx?record=WD10%2f1737%5Bv8%5D&dbid=AP&chksum=kGZLk7skelMkbw36%2bv3Arg%3d%3d.


119 For example, in Western Australia, the Medicines and Poisons Branch of the WA Department of Health is responsible for administration of the *Medicines and Poisons Act 2014* (WA); https://www2.health.wa.gov.au/Articles/N_R/Pharmaceutical-Services-Branch, in New South Wales, the Chief Pharmacist Unit and the Pharmaceutical Regulatory Unit within the New South Wales Ministry of Health are responsible for administration of the *Poisons and Therapeutic Goods Act 1966* (NSW); https://www.health.nsw.gov.au/pharmaceutical/Pages/about-us.aspx.


Providers may implement policies concerning administration of medication by personal care workers employed in their facilities, which may vary from provider to provider.122

The Australian Government subsidises the cost of prescription medicines to the Australian public through the Pharmaceutical Benefits Scheme under the National Health Act 1953 (Cth). Subsidies are also provided to veterans through the Repatriation Pharmaceutical Benefits Scheme (RPBS) under the Veteran’s Entitlements Act 1986 (Cth).

Medicines that can be subsidised under the Pharmaceutical Benefits Scheme are listed in the National Health (listing of Pharmaceutical Benefits) Instrument 2012. Under the Pharmaceutical Benefits Scheme, most medicines are listed as ‘unrestricted benefits’, meaning that a benefit will be paid if the medicine is prescribed (and dispensed) for the Therapeutic Goods Administration (TGA) approved indication. Use of medications for indications other than as specified in the Therapeutic Goods Administration approved product information (‘off-label’) is common in several areas of medicine particularly where evidence is less readily attainable (for example, paediatrics) or when economic factors limit applications for approval. However, there are significant issues associated with off-label medication to which prescribers must give careful consideration.123

Some medicines are listed as ‘restricted benefits’, meaning that a benefit will only be paid if the medicine is prescribed and dispensed for specific therapeutic uses. A subset of restricted benefits are ‘authority benefits’, which may be either:

- authority required (streamlined) benefits, meaning the prescriber must annotate the prescription with a code indicating for which indication the medicine is being prescribed; or
- authority required benefits, meaning the prescriber must seek the prior approval of the Department of Human Services to the prescription, having informed the Department of the indication.

The Practitioner Review Program analyses Medicare claims and Pharmaceutical Benefits Scheme prescribing data to identify servicing practices that differ from peers and which may indicate possible inappropriate practice.124

Legal frameworks relating to consent to care and treatment

States and territories administer legal frameworks that provide for decision making with respect to care and treatment, which are relevant to care and treatment provided to people in residential aged care. The common law has recognised the importance of informed consent to treatment125 and there may be legal consequences for providing care or treatment without lawful consent.126 In the states and territories, various legislation provides a framework for

125 Rogers v Whitaker (1992) 175 CLR 479.
determining when a person has impaired capacity affecting their ability to consent or make decisions about their care or medical treatment. The legislation provides for authorisation of substitute decision makers for people with impaired capacity.

The statutory frameworks allow people who have the capacity to make arrangements for their future care and medical treatment through the appointment of a substitute decision maker or advance care directive that will apply if the person does not have capacity to make a decision about care or treatment at the time a decision is required.127

State and territory legislation determines who may provide lawful consent to medical treatment on behalf of a person with impaired capacity.128 For example, in New South Wales if a medical practitioner believes that a person has impaired capacity and is unable to make a decision concerning their care, they must seek consent from a person who is authorised to provide consent under the Guardianship Act 1987 (NSW).

Civil and administrative tribunals in each of the states and territories have jurisdiction to determine matters concerning the health and welfare of adults with impaired capacity, including appointment of a substitute decision maker, such as a guardian.129

The legislation variously sets out principles to be applied in authorisation of substitute decision makers and exercise of powers as a substitute decision maker. Some state and territory legislation includes express provisions concerning authorisation and use of restrictive practices. In South Australia, for example, the legal framework explicitly provides for a tribunal to determine where a person should live, detention in that place and use of force in providing care or treatment.130

In the mental health setting, state and territory legislation provides for detention and administration of medication for mental disorder without patient consent.131 States and territories have also developed relevant policy guidance.132 There are number of statutory safeguards to protect the rights of people who receive treatment for mental illness under state and territory mental health legislation, including with respect to the use of restrictive practices.

127 See, for example, Medical Treatment Planning and Decisions Act 2016 (Vic) ss 26,50; Advance Care Directives Act 2013 (SA) s 23; Powers of Attorney Act 1998 (Qld) s 35; Advance Personal Planning Act 2013 (NT) s 8; Medical Treatment (Health Directions) Act 2006 (ACT) s 7; Guardianship Act 1987 (NSW) ss 6, 6G.

128 See, for example, Consent to Medical Treatment and Palliative Care Act 1995 (SA) Pt 2A; Guardianship and Administration Act 2000 (Qld) ss 11, 65, 66; Medical Treatment Planning and Decisions Act 2016 (Vic) ss 1, 4, 26, 50; Guardianship and Administration Act 1995 (Tas) ss 25, 39; Guardianship Act 1987 (NSW) ss 6E-F; Guardianship and Administration Act 1990 (WA) s 45, Pt 9D.

129 See, for example, Guardianship and Administration Act 1993 (SA) s 29; Guardianship and Administration Act 2000 (Qld) s 12; Guardianship and Administration Act 1986 (Vic) s 22; Guardianship of Adults Act 2016 (NT) s 11; Guardianship and Administration Act 1995 (Tas) s 20; Guardianship and Management of Property Act 1991 (ACT) s 7; Guardianship and Administration Act 1990 (WA) s 40; Guardianship Act 1987 (NSW) Pt 3.

130 See Guardianship and Administration Act 1993 (SA) s 32(1) under which the South Australian Civil and Administrative Tribunal is empowered to determine where a person should live including detention in that place and may authorise use of force in providing care and treatment.

131 See, for example, Disability Services Act 2006 (Qld); Mental Health Act 2016 (Qld); Disability Inclusion Act 2014 (NSW); Mental Health Act 2007 (NSW); Mental Health Act 2014 (Vic); Mental Health Act 2009 (SA).

132 See, for example, SA Health, Restraint and Seclusion in Mental Health Services Policy Guideline, 2015.
Some states and territories have legislation that explicitly regulates restrictive practices in
disability services. The states and territories endorsed the National Framework for
Reducing and Eliminating the Use of Restrictive Practices in the Disability Service Sector
(National Framework) in March 2014, which was intended to inform the development of the
National Disability Insurance Scheme (NDIS) quality assurance system and would provide a
national approach to use of restrictive practices in disability services. The National
Disability Insurance Scheme Commission will begin to regulate providers operating in
Victoria, Queensland, Tasmania, Australian Capital Territory and Northern Territory from
1 July 2019 and Western Australia from 1 July 2020.

The use of terminology across the legislation, the legal basis for identifying a person has
impaired capacity, appointment of substitute decision makers, the powers and duties of
persons who may act as a substitute decision maker for a person with impaired capacity and
the principles by which decisions are to be made, are not consistent. There is variation in the
extent to which restrictive practices are explicitly regulated and safeguards that apply.

It has also been observed that statutory schemes that authorise care and treatment including
restraint of people with impaired mental capacity without their informed consent apply in
limited circumstances and the common law doctrine of necessity may not provide an
adequate legal basis for restraint.

Australia’s human rights obligations

Australia has agreed to be bound by human rights treaties that recognise and protect the
human rights of all people equally, which include implicit obligations towards older people.
The rights enshrined in the International Covenant on Civil and Political Rights include rights
to self-determination, liberty and security of the person, recognition and equality before
the law. The International Covenant on Economic, Social and Cultural Rights protects the
right to enjoyment of the highest attainable standards of physical and mental health. The
Convention against Torture and Other Cruel, Inhuman or Degrading Treatment (CAT) may
also be relevant in the context of restraints in residential aged care.

The Convention on the Rights of Persons with Disabilities clarifies the application of human
rights to people with disabilities, including older people with physical or mental

---

133 See, for example, Disability Act 2006 (Vic) Pt 7.
137 International Covenant on Civil and Political Rights Art 1(1).
138 Ibid, Art 9(1).
140 International Covenant on Economic, Social and Cultural Rights Art 12.
141 Australian Law Reform Commission, above n 126, p 39. Australia has ratified the Optional Protocol to the Convention against Torture and other Cruel, Inhuman and Degrading Treatment (OPCAT). The objective of the OPCAT is to establish a system of regular visits undertaken by independent international and national bodies to places where people are deprived of their liberty, in order to prevent torture and other cruel, inhuman or degrading treatment or punishment. A residential care home where people may not be free to leave could fall within the scope of a ‘place of detention.’
The Convention reiterates the principle of personal autonomy. In ratifying the Convention, Australia accepted obligations with respect to promoting mobility, independence and the highest attainable standard of health for people with disabilities (including requiring free and informed consent). Within the Convention, it is acknowledged that the existence of a disability does not justify a deprivation of liberty. The right to equal recognition before the law, including support needed to exercise legal capacity, is enshrined within the convention.

While not enforceable unless incorporated into domestic law, human rights treaties are a statement of what Australia and the international community agree to be fundamental human rights. The treaties inform interpretation of existing laws and development of new legal frameworks. Where not already provided for in existing legislative or other arrangements, in signing the treaties the Australian Government has undertaken to take steps necessary to adopt legislative or other measures necessary to give effect to the recognised rights.

**Previous enquiries and recommendations**

Several enquiries and reviews have considered the issue of restrictive practices in residential aged care in Australia. Recent enquiries by the Australian Law Reform Commission, and Ms Kate Carnell and Professor Ron Paterson (Carnell and Paterson) concluded that legislative reform, including explicit regulation of restrictive practices in residential aged care in Australia, is needed.

The Australian Law Reform Commission highlighted the ‘patchwork’ of federal, state and territory laws and policies that apply to restrictive practices and has recommended development of a national approach to regulation of restrictive practices in aged care. It recommended amendment of aged care legislation and a review of state and territory laws concerning decision making, to provide a consistent decision making model and promote supported decision making in statutory decision making frameworks. Specifically, it recommended that:

---


143 *Convention on the Rights of Persons with Disabilities* Art 3(1).

144 Ibid, Art 20.


146 Ibid, Art 14.

147 Ibid, Art 12.


151 Australian Law Reform Commission, above n 126, p 248.

152 Ibid, p 170.

153 Ibid, pp 21, 274.


155 Ibid.
The Aged Care Act 1997 (Cth) should be amended to include provisions dealing with supporters and representatives consistent with the Commonwealth decision-making model [recommended by the ALRC].

... State and territory governments should review laws and legal frameworks concerning individual decision-making to ensure they are consistent with the National Decision-Making Principles and the Commonwealth decision-making model. In conducting such a review, regard should also be given to:

a. interaction with any supporter and representative schemes under Commonwealth legislation;
b. consistency between jurisdictions, including in terminology;
c. maximising cross-jurisdictional recognition of arrangements; and
d. mechanisms for consistent and national data collection.

Any review should include, but not be limited to, laws with respect to guardianship and administration; consent to medical treatment; mental health; and disability services.

While aiming to discourage the use of restrictive practices, the Australian Law Reform Commission recommended legislative regulation of restrictive practices in residential care facilities include the following principles:156

- least restrictive option;
- as a last resort;
- where necessary to prevent serious physical harm;
- the extent necessary and proportionate to the risk of harm;
- with approval by a person authorised by statute;
- as documented in a person’s support plan;
- when subject to regular review.

The Australian Law Reform Commission also recommended additional oversight mechanisms, including a senior practitioner to provide expert leadership and oversight of the use of restrictive practices in aged care and disability services, and mandatory reporting on the use of restrictive practices.157 It proposed development of a consistent national approach to the regulation or restrictive practices.158

Carnell and Paterson supported the principles recommended by the Australian Law Reform Commission as key elements for inclusion in standards limiting the use of restrictive practices in aged care. In addition, they recommended that:159

- approved providers be required to record and report the use of restrictive practices in residential aged care to the Aged Care Quality and Safety Commission;
- accreditation assessments review the use of psychotropic agents;

---

156 Australian Law Reform Commission, above n 3, pp 142, 143.
157 Ibid, pp 142, 146.
158 Australian Law Reform Commission, above n 126, p 256.
159 Ibid, p 126.
• a Chief Clinical Advisor approve the use of antipsychotic medications for aged care residents.

Carnell and Paterson also recommended that the Chief Clinical Advisor appointed to the Aged Care Quality and Safety Commission develop professional guidance to reduce the use of restrictive practices.\(^{160}\)

Both the Australian Law Reform Commission and Carnell and Paterson made observations as to the significance and gravity of the inappropriate use of restraints in recommending explicit regulation and suggested that governments and providers should aspire to eliminate restrictive practices.\(^{161}\)

In 2017, the Victorian Institute of Forensic Medicine published a number of recommendations for prevention of injury-related deaths in residential aged care facilities. In the case of physical restraint, it made 15 recommendations.\(^{162}\) At the heart of those recommendations is the need for residential aged facilities to focus on and be supported in sustaining a person-centred care approach that respects the human rights of each person. Other recommendations include that:\(^{163}\)

- physical restraint only occur in extremely limited circumstances and should involve at least two health professionals with documented reasons for the use, duration of use, outcome of restraint and any adverse events;
- facilities have a physical restraint policy that promotes alternative approaches but mandates that if restraint is to be imposed, the limits of the restraint are documented;
- use of physical restraint mandate specialist review of the resident’s care plan to as to identify a strategy to eliminate or reduce the need for restraint; and
- restraint be instituted and monitored by staff with formal training and demonstrated competency to intervene in such a way.

**Conclusions**

Restraint impacts the rights and dignity of older people in residential aged care. There is significant public interest in the issue of restraint and ways to reduce or avoid its use.

Some consider physically restricting a resident’s movements, or administering medication that can have a restrictive effect on a resident, is justified in some circumstances when providing care or medical treatment. However, there is a body of evidence that identifies significant risks to older people associated with the use of both physical restraint and medications, such as psychotropic medications, that affect a resident’s movement or ability to make decisions. Current professional standards and guidance applicable to residential aged care indicate alternatives to restraint should be attempted before restraint is used.

There is no reliable data that reveals the prevalence of the use of physical or chemical restraint. Some research suggests there is significant variability between residential care

\(^{160}\) Ibid, p 125.
\(^{161}\) Australian Law Reform Commission, above n 3, p 145.
facilities in the extent to which physical restraint occurs. Studies have indicated rates of psychotropic use by residents in aged care are high but this may also vary significantly between residential aged care facilities. Inconsistencies in the definition of restraint contribute to uncertainty about the prevalence of restraint in residential aged care.

The regulation of care and treatment of residents in aged care facilities, including restrictive practices, occurs through state and territory as well as Commonwealth legislation. A patchwork of legal frameworks applies to approval and funding of residential aged care providers, regulation of health practitioners, prescription and administration of medication and decision-making processes concerning care and treatment of people with impaired capacity. Previous enquiries have concluded legislation concerning restrictive practices needs reform. The Australian Government has recently made amendments to legislative requirements concerning restraint that will apply to aged care providers. Further inquiry is required into the nature and extent of restraint occurring in residential aged care, how best to deliver person-centred care services to people residing in aged care facilities (including those who have impaired cognition such as those living with dementia), and the systems including legal frameworks required to ensure the safety and quality of residential care services.
Appendix

The medicines tables below provide examples of psychotropic medicines and other medicines of interest available in Australia. Information is provided on: the conditions that the medicine is approved to treat; whether the medicine is subsidised by the Australian Government through the Pharmaceutical Benefits Scheme (PBS); and PBS Section 85 prescription volumes for financial year 2017–18.

- Table 1: Antipsychotics
- Table 2: Drugs to slow progression of Dementia
- Table 3: Benzodiazepines + other sedatives/hypnotics/anxiolytics
- Table 4: Opioid analgesics
- Table 5: Antidepressants
- Table 6: Miscellaneous items of interest

Types of PBS Benefits as described on the PBS online website (screenshots of PBS medicines that fall into each of these categories attached at the end of this document): 164

- **Unrestricted Benefits**—where the doctor can prescribe through the PBS without restrictions on therapeutic use.
- **Restricted Benefits**—where the doctor can prescribe through the PBS when satisfied that the patient’s clinical condition matches the approved therapeutic uses, as determined by the Pharmaceutical Benefits Advisory Committee (PBAC).
- **Authority Required (STREAMLINED)**—where the doctor can prescribe through the PBS for specific conditions by providing a 4 digit streamlined authority code.
- **Authority Required**—where the doctor can prescribe through the PBS only if prior approval is obtained from the Department of Human Services or Department of Veterans Affairs. Some items require authority in writing to be obtained from the Department of Human Services.

To reflect this, the tables below have been coded with PBS Listing statuses:

| U = Unrestricted | R = Restricted | A = Authority Required | AS = Authority Required (STREAMLINED) |

Medicines can be listed in more than one of the above PBS benefit categories. For example, Oxazepam is listed on the PBS as an unrestricted item for a single pack of 25 x 15mg tablets with no repeats. If a prescriber wants to write a prescription for Oxazepam 50 x 15mg tablets with 2 repeats, this will need to be written as an Authority prescription. Different formulations or strengths of a medicine may also have different PBS listing categories—e.g. Morphine tablets may have different PBS listing criteria compared to Morphine liquid in ampoules for injection.

All PBS indications are sourced from individual PBS medicine listings as of April 2019. All Therapeutic Goods Administration (TGA) indications are sourced from individual medicine summaries provided on the Australian Register of Therapeutic Goods as of April 2019.165 PBS listing indications and TGA treatment indications have sometimes been summarised for brevity. PBS 2017-18 prescription volumes have been generated using publicly available Section 85 date of supply data that was updated in April 2019.166 PBS prescription volumes include above and below co-payment prescriptions for all patient categories, including prescriber bag items. RPBS items are also included.


Table 1: Antipsychotics

<table>
<thead>
<tr>
<th>Medicine name</th>
<th>PBS Listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amisulpride AS</td>
<td>• Schizophrenia</td>
<td>• Acute and chronic schizophrenic disorders</td>
<td></td>
<td>87,292</td>
</tr>
<tr>
<td>Aripiprazole AS</td>
<td>• Schizophrenia</td>
<td>• Schizophrenia including maintenance therapy</td>
<td></td>
<td>302,281</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Acute treatment of manic or mixed episodes associated with Bipolar I Disorder in adults</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Maintenance treatment of manic or mixed episodes in Bipolar I Disorder in adults</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asenapine AS</td>
<td>• Schizophrenia</td>
<td>• Schizophrenia in adults</td>
<td></td>
<td>25,394</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Treatment of acute manic or mixed episodes associated with Bipolar I Disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Prevention of relapse of manic or mixed episodes in Bipolar I Disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brexpiprazole AS</td>
<td>• Schizophrenia</td>
<td>• Treatment of schizophrenia</td>
<td></td>
<td>9,368</td>
</tr>
<tr>
<td>Chlorpromazine U</td>
<td></td>
<td>• Acute functional psychosis</td>
<td></td>
<td>71,282</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Long-term treatment of schizophrenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Short-term treatment of agitation and/or behavioural disturbance in patients with delirium or dementia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Short-term treatment of agitation and severe depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Severe behavioural disturbances, as can be found in some children with mental retardation or autism</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Management of terminal illness to enhance the effect of analgesics and to control nausea and vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Control of intractable hicchough</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clozapine AS * S100 Highly Specialised Drug</td>
<td>• Schizophrenia under the treatment of a psychiatrist or with the agreement of one when patient non-responsive or intolerant of other neuroleptic agents</td>
<td>• Treatment-resistant schizophrenia, when non-responsive to, or intolerant of other antipsychotic drugs</td>
<td>Not available in Section 85 PBS data</td>
<td></td>
</tr>
<tr>
<td>Flupentixol U</td>
<td></td>
<td>• Maintenance treatment of chronic schizophrenia and other chronic psychoses, in patients intolerant of and/or refractory to other depot preparations; not for short-term use (less than 3 months)</td>
<td></td>
<td>13,825</td>
</tr>
<tr>
<td>Medicine name</td>
<td>PBS Listed item?</td>
<td>PBS Indication(s) if medicine is only available as authority or restricted prescription</td>
<td>TGA indication(s)</td>
<td>PBS 2017-18 prescription volume</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>-------------------------------</td>
</tr>
</tbody>
</table>
| Haloperidol   | U                | • Management of psychotic disorders  
• Manic phase of manic depressive illness  
• Gilles de la Tourette syndrome  
• For the relief of delusions, hallucinations and confused states in acute alcoholism  
• Treatment of intractable nausea and vomiting associated with radiation or malignancy | • Treatment of schizophrenia in adults and adolescents (aged 13 to 17 years) | 89,967 |
| Lurasidone    | AS               | • Schizophrenia | • Treatment of schizophrenia in adults and adolescents (aged 13 to 17 years) | 92,664 |
| Olanzapine    | AS               | • Schizophrenia  
• Bipolar I | • Treatment of schizophrenia and related psychoses  
• Acute manic episodes associated with the short-term treatment of with Bipolar I Disorder  
• Preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder | 1,088,930 |
| Paliperidone  | AS               | • Schizophrenia | • Acute and maintenance treatment of schizophrenia in adult patients | 202,572 |
| Periciazine   | U                | | • Severe anxiety and tension states and the maintenance treatment of the psychotic patient; useful in controlling such symptoms as impulsiveness and aggression | 51,336 |
| Quetiapine    | AS               | • Schizophrenia  
• Bipolar I  
• Acute mania associated with bipolar I | • Schizophrenia  
• Bipolar disorder—maintenance and treatment of acute mania and depressive disorders  
• Major depressive disorder  
• Generalised anxiety disorder | 1,081,129 |
| Risperidone   | AS               | • Schizophrenia  
• Acute mania in bipolar I  
• Bipolar I  
• Behavioural disturbances in patients with Alzheimer’s type dementia who are unresponsive to non-pharmacological treatment for up to 12 weeks  
• Severe behavioural disturbances in patients with autism | • Schizophrenia and related psychoses  
• Short term treatment of acute mania in Bipolar I disorder  
• Bipolar I  
• Psychotic symptoms, agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe Alzheimer type dementia (up to 12 weeks)  
• Treatment of conduct and other disruptive behaviour disorders in children, adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours are prominent  
• Treatment of behavioural disorders associated with autism in children and adolescents | 591,841 |
<table>
<thead>
<tr>
<th>Medicine name</th>
<th>PBS Listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
</table>
| Ziprasidone   | AS               | • Schizophrenia  
• Acute mania or mixed episodes associated with bipolar I disorder | • Treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy  
• Short term treatment of acute manic or mixed episodes associated with bipolar I disorder | 32,165            |
| Zuclopenthixol | U                | • Treatment of acute psychoses, mania and exacerbation of chronic psychoses       |                  | 38,157            |

* PBS S100 Highly Specialised Drugs have PBS restrictions which apply to their prescribing and supply.\(^{167}\)

\(^{167}\) Department of Health, *Pharmaceutical Benefits Scheme Browse by Section 100 Item list: Section 100—items available under special arrangement*, https://www.pbs.gov.au/browse/section100.
Table 2: Drugs to slow progression of Dementia

<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>Medication Class</th>
<th>PBS listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donepezil</td>
<td>Anticholinesterase</td>
<td>AS</td>
<td>• Mild to Moderately Severe Alzheimer’s Disease</td>
<td>• Treatment of mild, moderate and severe Alzheimer’s disease</td>
<td>380,529</td>
</tr>
<tr>
<td>Galantamine</td>
<td>Anticholinesterase</td>
<td>AS</td>
<td>• Mild to Moderately Severe Alzheimer’s Disease</td>
<td>• Treatment of mild to moderately severe dementia of the Alzheimer type</td>
<td>79,325</td>
</tr>
<tr>
<td>Memantine</td>
<td>N-methyl-D-aspartate antagonist</td>
<td>AS</td>
<td>• Moderately Severe Alzheimer’s Disease as the sole PBS subsidised therapy</td>
<td>• Treatment of the symptoms of moderately severe to severe Alzheimer’s disease</td>
<td>49,037</td>
</tr>
<tr>
<td>Rivastigmine</td>
<td>Anticholinesterase</td>
<td>AS</td>
<td>• Mild to Moderately Severe Alzheimer’s Disease</td>
<td>• Treatment of mild to moderately severe dementia of the Alzheimer’s type</td>
<td>70,231</td>
</tr>
</tbody>
</table>
Table 3: Benzodiazepines + other sedatives/hypnotics/anxiolytics

<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>Medicine class</th>
<th>PBS Listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprazolam</td>
<td>Benzodiazepine</td>
<td>A</td>
<td>• Panic disorder where other treatments have failed or are inappropriate</td>
<td>• Short term treatment of anxiety, including anxious patients with depression</td>
<td>114,857</td>
</tr>
<tr>
<td>Bromazepam</td>
<td>Benzodiazepine</td>
<td>A *RPBS only</td>
<td>• Short term treatment of terminal disease where patient is receiving palliative care</td>
<td>• Symptomatic relief of tension, anxiety and agitation</td>
<td>538</td>
</tr>
<tr>
<td>Buspirone</td>
<td>Non-benzodiazepine anxiolytic</td>
<td>A *RPBS only</td>
<td>• Short term treatment of anxiety</td>
<td>• Not listed on the ARTG. Accessed through the Special Access Scheme</td>
<td>40</td>
</tr>
<tr>
<td>Clobazam</td>
<td>Benzodiazepine</td>
<td>Not PBS listed</td>
<td>• Anxiety</td>
<td>• Short-term treatment of insomnia associated with anxiety</td>
<td>Not PBS listed</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>Benzodiazepine</td>
<td>U, R, A</td>
<td>• Most types of epilepsy in children</td>
<td>• Intravenous use for status epilepticus</td>
<td>55,716</td>
</tr>
<tr>
<td>Medicine Name</td>
<td>Medicine class</td>
<td>PBS Listed item?</td>
<td>PBS Indication(s) if medicine is only available as authority or restricted prescription</td>
<td>TGA indication(s)</td>
<td>PBS 2017-18 prescription volume</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Diazepam</td>
<td>Benzodiazepine</td>
<td>U, A</td>
<td>• Short term treatment of anxiety&lt;br&gt;• Acute agitation, tremor, delirium and hallucinosis in alcohol withdrawal&lt;br&gt;• Reflex muscle spasm due to local trauma to muscles, bones and joints&lt;br&gt;• Spasticity due to upper motor neuron lesions such as cerebral palsy and paraplegia, as well as in athetosis and stiff-man syndrome&lt;br&gt;• Intravenous use for controlling status epilepticus and the spasms of tetanus</td>
<td>PBS 2017-18 prescription volume</td>
<td>2,511,445</td>
</tr>
<tr>
<td>Flunitrazepam</td>
<td>Benzodiazepine</td>
<td>A *RPBS only</td>
<td>• Short term treatment of terminal disease where patient is receiving palliative care.&lt;br&gt;• Short term treatment of refractory phobic or anxiety states</td>
<td>• Severe cases of insomnia</td>
<td>1,584</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>Benzodiazepine</td>
<td>Not PBS listed</td>
<td>• Anxiety disorders&lt;br&gt;• Short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms&lt;br&gt;• Pre-surgical medication taken the night before surgery and/or 1–2 hours prior to the surgical procedure</td>
<td>Not PBS listed</td>
<td></td>
</tr>
<tr>
<td>Medicine Name</td>
<td>Medicine class</td>
<td>PBS Listed item?</td>
<td>PBS Indication(s) if medicine is only available as authority or restricted prescription</td>
<td>TGA indication(s)</td>
<td>PBS 2017-18 prescription volume</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
</tr>
</tbody>
</table>
| Midazolam     | Benzodiazepine | Prescriber 's Bag only<sup>168</sup> | • Intravenously for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures  
• Intravenously for induction of anaesthesia, preliminary to administration of other anaesthetic agents  
• Intramuscularly for preoperative sedation and to impair memory of perioperative events  
• Intravenous use for status epilepticus | | 4,917 |
| Nitrazepam    | Benzodiazepine | U, A | • Insomnia | | 253,686 |
| Oxazepam      | Benzodiazepine | U, A | • Management of anxiety disorders  
• Short-term relief of the symptoms of anxiety including anxiety associated with depression  
• Alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal | | 974,474 |
| Temazepam     | Benzodiazepine | U, A | • Adjunctive therapy for the short term management of insomnia in adults | | 2,012,139 |
| Zolpidem      | Non-benzodiazepine hypnotic | Not PBS listed | • Short term treatment of insomnia in adults | Not PBS listed | |
| Zopiclone     | Non-benzodiazepine hypnotic | R *RPBS only | • Short term treatment of insomnia | • Short-term treatment of insomnia (two to four weeks). | 23,583 |

* RPBS = Repatriation item only available on the Repatriation PBS to those who have a valid Health card issued by the Department of Veterans Affairs.<sup>169</sup>

Flunitrazepam and Alprazolam are Schedule 8 Controlled Drugs subject to additional state and territory legislative requirements when prescribing, dispensing and storing.

---


## Table 4: Opioid analgesics

<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>PBS listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
</table>
| Buprenorphine| R, A + S100 opiate dependence program | • Restricted to treatment for chronic severe disabling pain unresponsive to non-opioid analgesics  
• Authority required for treatment of chronic severe disabling pain when patient is receiving palliative care  
• Treatment of opiate dependence under the S100 Opiate dependence program | • Management of moderate to severe pain  
• Treatment of opiate dependence | 1,419,797 (S85 prescription volume only) |
<p>| Codeine      | U                | • Relief of unproductive, dry and intractable coughs associated with colds and flu |                  | 217,897                         |
| Codeine + Aspirin | U *RPBS only | • Temporary relief of acute moderate pain, inflammation and fever |                  | 303                            |
| Codeine + Paracetamol | U, A           | • Temporary relief of moderate to severe pain and fever |                  | 3,819,756                      |</p>
<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>PBS listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
</table>
| Fentanyl      | R, A             | • Restricted to treatment for chronic severe disabling pain unresponsive to non-opioid analgesics  
• Authority required for treatment of breakthrough pain when patient is receiving palliative care and has cancer | • Management of chronic pain requiring opioid analgesia  
• Management of breakthrough cancer pain in patients with malignancies who are already receiving and tolerant to opioid therapy  
• Adjunct during general anaesthesia | 507,008 |
| Hydromorphone | U, R             | • Relief and treatment of moderate to severe pain, including chronic pain |                                | 166,411 |
| Methadone     | R, A, S100 opiate dependence program | • Restricted to treatment for severe disabling pain unresponsive to non-opioid analgesics  
• Authority required for chronic severe disabling pain in palliative care  
• Treatment of opiate dependence under the S100 Opiate dependence program | • Analgesic in conditions where morphine would make a reasonable alternative  
• Treatment of opioid drug addictions as substitute or maintenance therapy under specialist supervision | 87,385 (S85 prescription volume only) |
| Morphine      | U, R, A          | • Prolonged relief of chronic, moderate to severe pain  
• Treatment of chronic severe cancer pain, including in terminal cancer patients  
• Pre-operative medication and analgesic adjunct in general anaesthesia |                                | 534,451 |
<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>PBS listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxycodone</td>
<td>R</td>
<td>• Restricted to treatment for severe disabling pain, including chronic pain, unresponsive to non-opioid analgesics</td>
<td>• Management of opioid responsive moderate to severe pain</td>
<td>3,532,476</td>
</tr>
<tr>
<td>Oxycodone + Naloxone</td>
<td>R</td>
<td>• Restricted to treatment for chronic severe disabling pain unresponsive to non-opioid analgesics</td>
<td>• Management of moderate to severe pain with naloxone used for prophylaxis of opioid induced constipation • Symptomatic treatment of patients with severe to very severe idiopathic restless leg syndrome after failure of dopaminergic therapy</td>
<td>2,245,258</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>R</td>
<td>• Restricted to treatment for chronic severe disabling pain unresponsive to non-opioid analgesics</td>
<td>• Management and relief of moderate to severe chronic pain unresponsive to non-narcotic analgesia</td>
<td>737,020</td>
</tr>
<tr>
<td>Tramadol</td>
<td>R</td>
<td>• Restricted to acute treatment of short term pain • Restricted to treatment of pain, including chronic pain, where aspirin and/or paracetamol alone are inappropriate or have failed</td>
<td>• Relief of moderate to severe pain</td>
<td>2,702,883</td>
</tr>
</tbody>
</table>

* RPBS = Repatriation item only available on the Repatriation PBS to those who have a valid Health card issued by the Department of Veterans Affairs.\(^{170}\)

All opioid medicines are Schedule 8 Controlled drugs except for Tramadol, and Codeine in combination with paracetamol or aspirin.

\(^{170}\) Ibid.
Table 5: Antidepressants

<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>PBS listed item?</th>
<th>PBS Indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication(s)</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agomelatine</td>
<td>Not PBS Listed</td>
<td>• Major depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>U</td>
<td>• Major depressive disorders • Nocturnal emesis where organic pathology excluded</td>
<td></td>
<td>2,269,130</td>
</tr>
<tr>
<td>Citalopram</td>
<td>U</td>
<td>• Major depression</td>
<td></td>
<td>1,764,134</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>R</td>
<td>• Cataplexy associated with narcolepsy • Obsessive-compulsive disorder • Phobic disorders in adults</td>
<td>• Cataplexy associated with narcolepsy • Obsessive-compulsive disorder • Phobic disorders in adults</td>
<td>81,061</td>
</tr>
<tr>
<td>Desvenlafaxine</td>
<td>R</td>
<td>• Major depressive disorders</td>
<td>• Major depression</td>
<td>2,231,557</td>
</tr>
<tr>
<td>Dosulepin/Dothiepin</td>
<td>U</td>
<td>• Major depression</td>
<td></td>
<td>352,373</td>
</tr>
<tr>
<td>Doxepin</td>
<td>U</td>
<td>• Major depression</td>
<td></td>
<td>195,867</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>R</td>
<td>• Major depressive disorders • Major depression • Diabetic peripheral neuropathic pain • Generalised anxiety disorder</td>
<td>• Major depression • Generalised anxiety disorder • Social anxiety disorder • Obsessive compulsive disorder</td>
<td>1,674,480</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>R</td>
<td>• Major depressive disorders • Moderate to severe generalised anxiety disorder • Moderate to severe social anxiety disorder</td>
<td>• Major depression • Obsessive-compulsive disorder</td>
<td>4,187,423</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>R</td>
<td>• Major depressive disorders • Obsessive-compulsive disorder</td>
<td>• Major depression • Obsessive-compulsive disorder • Premenstrual dysphoric disorder</td>
<td>1,961,918</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>R</td>
<td>• Major depressive disorders • Obsessive-compulsive disorder</td>
<td>• Major depression • Obsessive-compulsive disorder</td>
<td>441,536</td>
</tr>
<tr>
<td>Imipramine</td>
<td>U</td>
<td>• Major depression • Nocturnal emesis provided organic causes have first been excluded</td>
<td></td>
<td>19,271</td>
</tr>
<tr>
<td>Mianserin</td>
<td>R</td>
<td>• Severe depression</td>
<td>• Major depression</td>
<td>41,632</td>
</tr>
<tr>
<td>Medicine Name</td>
<td>PBS listed item?</td>
<td>PBS Indication(s) if medicine is only available as authority or restricted prescription</td>
<td>TGA indication(s)</td>
<td>PBS 2017-18 prescription volume</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>R</td>
<td>• Major depressive disorders • Major depression including relapse prevention</td>
<td></td>
<td>2,525,915</td>
</tr>
<tr>
<td>Moclobemide</td>
<td>R</td>
<td>• Major depressive disorders • Major depression</td>
<td></td>
<td>106,348</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>R</td>
<td>• Major depression where other anti-depressant therapy has failed • Major depression</td>
<td></td>
<td>165,206</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>R</td>
<td>• Major depressive disorders • Obsessive-compulsive disorder • Panic disorder</td>
<td>• Major depression • Obsessive-compulsive disorder • Panic disorder • Social anxiety disorder/social phobia • Generalised anxiety disorder • Post-traumatic stress disorder</td>
<td>1,030,623</td>
</tr>
<tr>
<td>Phenelzine</td>
<td>R</td>
<td>• Depression where all other anti-depressants have failed or are inappropriate • Major depression. Should rarely be the first antidepressant drug used.</td>
<td></td>
<td>6,790</td>
</tr>
<tr>
<td>Reboxetine</td>
<td>R</td>
<td>• Major depressive disorders • Major depression</td>
<td></td>
<td>44,392</td>
</tr>
<tr>
<td>Sertraline</td>
<td>R</td>
<td>• Major depressive disorders • Obsessive-compulsive disorder • Panic disorder</td>
<td>• Major depression • Obsessive compulsive disorder • Panic disorder • Social anxiety disorder/social phobia • Premenstrual dysphoric disorder</td>
<td>4,104,221</td>
</tr>
<tr>
<td>Tranylcypromine</td>
<td>U</td>
<td>• Treatment of major depressive disorders • Major depression</td>
<td></td>
<td>17,511</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>R</td>
<td>• Major depressive disorders • Generalised anxiety disorder • Social anxiety disorder • Panic disorder</td>
<td></td>
<td>3,036,319</td>
</tr>
<tr>
<td>Vortioxetine</td>
<td>Not PBS Listed</td>
<td>• Major depressive disorders • Major depressive disorders</td>
<td></td>
<td>Not PBS Listed</td>
</tr>
</tbody>
</table>
### Table 6: Miscellaneous items of interest

<table>
<thead>
<tr>
<th>Medicine Name</th>
<th>Medicine Class</th>
<th>PBS listed item?</th>
<th>PBS indication(s) if medicine is only available as authority or restricted prescription</th>
<th>TGA indication</th>
<th>PBS 2017-18 prescription volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregabalin</td>
<td>Antiepileptic</td>
<td>AS</td>
<td>• Neuropathic pain refractory to treatment with other drugs</td>
<td>• Treatment of neuropathic pain in adults&lt;br&gt;• Indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation</td>
<td>4,076,599</td>
</tr>
</tbody>
</table>

Examples of PBS Medicines in the unrestricted, restricted, authority required (STREAMLINED) and authority required categories

**An unrestricted benefit:**

**OXAZEPAM**

<table>
<thead>
<tr>
<th>Source</th>
<th>General Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body System</td>
<td>NERVOUS SYSTEM &gt; PSYCHOLEPTICS &gt; ANXIOLYTICS</td>
</tr>
<tr>
<td>Note</td>
<td></td>
</tr>
</tbody>
</table>

**A restricted benefit:**

**MORPHINE**

<table>
<thead>
<tr>
<th>Source</th>
<th>General Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body System</td>
<td>NERVOUS SYSTEM &gt; ANALGESICS &gt; OPIOIDS</td>
</tr>
<tr>
<td>Note</td>
<td></td>
</tr>
</tbody>
</table>

**An Authority Required (STREAMLINED) benefit:**

**RISPERIDONE**

<table>
<thead>
<tr>
<th>Source</th>
<th>General Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body System</td>
<td>NERVOUS SYSTEM &gt; PSYCHOLEPTICS &gt; ANTIPSYCHOTICS</td>
</tr>
<tr>
<td>Note</td>
<td></td>
</tr>
</tbody>
</table>

**An Authority required benefit:**

**OXAZEPAM**